Biblio

Author Title [ Type

] Year

Filters: Author is Martino, Massimo [Clear All Filters]

Journal Article

Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AMaria, Cutini I, Dodero A, et al. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia. 2024.

Canale FAntonio, Pitea M, Alati C, Porto G, Pratico G, Utano G, Germanò J, Imbalzano L, Ferreri A, Verduci C, et al. Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation. Eur J Haematol. 2023.

Martino M, Gori M, Moscato T, Naso V, Ferreri A, Provenzano F, Loteta B, Sanguedolce MCristina, Console G, Dattola A, et al. The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts. Biol Blood Marrow Transplant. 2019.

Fedele R, Martino M, Recchia AGrazia, Irrera G, Gentile M, Morabito F. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. J Immunol Res. 2015;2015:968212.

Martino M, Gori M, Porto G, Pellicano M, Santoro L, Verduci C, Canale FAntonio, Loteta B, Moscato T, Alati C, et al. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023.

Martino M, Gori M, Porto G, Pellicano M, Santoro L, Verduci C, Canale FAntonio, Loteta B, Moscato T, Alati C, et al. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023.

Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, et al. GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. Transplant Cell Ther. 2021.

Bazarbachi A, Labopin M, Angelucci E, Gulbas Z, Ozdoğu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, et al. Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.

Martino M, Lanza F, Pavesi L, Öztürk M, Blaise D, Núñez RLeno, Schouten HC, Bosi A, De Giorgi U, Generali D, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in high-risk breast cancer: data from the EBMT registry. Biol Blood Marrow Transplant. 2015.

Necchi A, Lanza F, Rosti G, Martino M, Farè E, Pedrazzoli P. High-dose chemotherapy for germ cell tumors: do we have a model?. Expert Opin Biol Ther. 2014:1-12.

Mariotti J, Raiola AMaria, Evangelista A, Carella AMichele, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, et al. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv. 2020;4(16):3900-3912.

Delia M, Carluccio P, Mestice A, Chiusolo P, Metafuni E, Bellesi S, Arpinati M, Milone GAntonio, Martino M, Mazza P, et al. The impact of graft CD3/Tregs ratio on aGvHD and post-transplant outcome: a prospective multicenter study on patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. Transplant Cell Ther. 2021.

Mariotti J, Raiola AMaria, Evangelista A, Harbi S, Patriarca F, Carella MAngelo, Martino M, Risitano A, Busca A, Giaccone L, et al. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2022.

Morabito F, Recchia AGrazia, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, et al. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opin Pharmacother. 2019:1-10.

Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher GM, Capria S, Forcade E, et al. Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. Cancer. 2019.

Martino M, Canale FAntonio, Porto G, Verduci C, Utano G, Policastro G, Germanò J, Alati C, Santoro L, Imbalzano L, et al. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning. Expert Opin Biol Ther. 2023:1-9.

Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, et al. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023.

Canale FA, Martino M, Porto G, Verduci C, Console G, Irrera G, Loteta B, Naso V, Pugliese M, Moscato T, et al. The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic. Support Care Cancer. 2023;31(6):350.

Devillier R, Galimard J-E, Labopin M, Blaise D, Raiola AMaria, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022.